DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
Gamida Cell, a leading cellular and immune therapeutics company, today announced two presentations from its NiCord programs in high-risk hematologic malignancies and sickle cell disease (SCD) at the 2018 BMT Tandem Meetings, held from February 21 – 25 at the Salt Palace Convention Center in Salt Lake City, UT.
Details for the presentations are as follows:
-NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial; Mitchell Horwitz, M.D., Session G: Alternative Donor / Immune Reconstitution, Feb. 23, 2018 at 10:30 a.m. MT in Ballroom I
-A Novel Therapy for Sickle Cell Disease (SCD): Co-Transplantation of NiCord [Ex-Vivo Expanded Umbilical Cord Blood (UCB) Progenitor Cells with Nicotinamide] and an Unmanipulated Unrelated UCB Graft Leads to Successful Engraftment and Cure of Severe SCD; Suhag H. Parikh, M.D., Poster Session 1: Cord Blood, Feb. 21, 2018 at 6:45 p.m. MT in Hall E


Related Content
-
news & eventsSafety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
education & researchGuidelines on Red Cell Transfusion in Sickle Cell Disease. Part I: Principles and Laboratory AspectsBlood transfusion in the management of s...
-
education & researchClinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA u...Advances in allogeneic hematopoietic cel...
-
news & eventsSCDAA Masterclass Speaker Series: All Things Considered – SCD Treatment: A Personal ChoiceSCDAA's First Masterclass on the Cusp of...
-
news & eventsTeen with sickle cell disease takes class trip to Europe with Loyola Medicine’s helpAnyah Randolph, a teenager with sickle c...
-
videos & visualsBlood Transfusions: What You Need to Know and Do (Part 3: IRON OVERLOAD)https://www.youtube.com/watch?v=aXURPZav...
-
news & eventsAPS Scientific Meeting 2019The American Pain Society will hold its ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.